Document is current
Any future updates will be listed below
-
Authors
Eschen, Christian Kim
Banasik, Karina
Dahl, Anders Bjorholm
Chmura, Piotr Jaroslaw
Bruun-Rasmussen, Peter
Pedersen, Frants
Køber, Lars
Engstrøm, Thomas
Bøttcher, Morten
Winther, Simon
Christensen, Alex Hørby
Bundgaard, Henning
Brunak, Søren
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden (NNF17OC0027594, NNF17OC0027594, NNF17OC0027594)
Innovationsfonden (518-00102B, 518-00102B, 518-00102B)
Copenhagen University
- License Information
-
More Information
Article History
Received: 14 October 2024
Accepted: 1 January 2025
First Online: 9 January 2025
Declarations
:
: Søren Brunak has ownership in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S, Eli Lilly & Co and ALK Abello and has managing board memberships in Proscion A/S and Intomics A/S. Morten Bøttcher declares advisory board work for Astra Zeneca, Novo Nordisk A/S, Sanofi, Bayer, Pfizer/BMS, Acarix, Boehringer Ingelheim and Novartis. The remaining authors declare no conflicts of interests.
: Approval for data access was granted by the National Committee on Health Research Ethics (1708829 "Genetics of cardiovascular disease", ID P-2019-93), The Danish Data Protection Agency (ref: 514-0255/18-3000, 514-0254/18-3000, SUND-2016-50), and by the Danish Patient Safety Authority (3-3013-1731-1, appendix 31-1522-23). All personal identifiers were pseudo-anonymized.
